Molecular Formula | C20H20ClN3 |
Molar Mass | 337.85 |
Density | 1.214 |
Storage Condition | -20℃ |
In vitro study | AT7867 also inhibits the structurally related AGC kinases p70S6K and PKA with IC50 of 20 nM and 85 nM, respectively. When AT7867 inhibits AKT2, K I is 18 nM. AT7867 acts on cell lines carrying PTEN or PIK3CA mutations, has anti-proliferative activity, and efficiently acts on MES-SA, MDA-MB-468, MCF-7, HCT116 and HT29 with IC50 of 0.94 μ M and 2.26 μ M respectively, 1.86 μM, 1.76 μm and 3.04 μm. AT7867 also inhibited U87MG, PC-3 and DU145 cell growth with IC50 of 8.22 μm, 10.37 μm and 11.86 μm, respectively. AT7867 inhibits AKT activity by inhibiting phosphorylation of GSK3β in human tumor cells with an IC50 of 2-4 μm. AT7867, acting on U87MG cells, also induces phosphorylation of direct AKT substrates, including the pro-apoptotic transcription factors FKHR (FoxO1a), FKHRL1(FoxO3a), and the downstream target S6RP. |
In vivo study | AT7867 was administered to mice by oral treatment with a bioavailability of 44%. AT7867 was administered intraperitoneally at a dose of 20 mg/kg or orally at a dose of 90 mg/kg to MES-SA transplanted tumors and increase cleaved PARP. AT7867 significantly inhibited the growth of MES-SA or U87MG xenografts with T/C of 0.37 and 0.51, respectively. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.96 ml | 14.799 ml | 29.598 ml |
5 mM | 0.592 ml | 2.96 ml | 5.92 ml |
10 mM | 0.296 ml | 1.48 ml | 2.96 ml |
5 mM | 0.059 ml | 0.296 ml | 0.592 ml |